Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AYTU BIOPHARMA, INC (AYTU)

Aytu BioPharma Q3 net revenue falls to $12.4 million; net loss of $5.6 million

Negative Impact 3 of 5 earnings Written later

Aytu BioPharma reported fiscal 2026 third-quarter net revenue of $12.4 million, down from $18.5 million a year earlier, and a net loss of $5.6 million, compared with net income of $4.0 million in the prior-year quarter. The company attributed the revenue decline mainly to lower ADHD Portfolio and Pediatric Portfolio sales as its marketing shifted toward the newly launched EXXUA, which contributed $2.4 million.

Key points

  • Net revenue was $12.4 million versus $18.5 million in Q3 fiscal 2025; ADHD Portfolio fell to $9.1 million from $15.4 million.
  • EXXUA net revenue was $2.4 million; the product was made commercially available in mid-December 2025 and formally launched in mid-January 2026.
  • Net loss was $5.6 million, or $0.53 per basic share, versus net income of $4.0 million, or $0.65 per basic share; the result includes a $1.3 million derivative warrant liability loss.
  • Adjusted EBITDA was $(2.8) million versus $3.9 million a year earlier; cash and cash equivalents were $26.7 million at March 31, 2026.

The filing

CompanyAYTU BIOPHARMA, INC (AYTU)
Form8-K, current report
Filed with the SECMay 13, 2026, 4:05 PM ET
Accession number0001437749-26-016717

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.